文献速递淋巴瘤

四种CD20xCD3双特异性抗体对不同CD20表达水平弥漫大B细胞淋巴瘤细胞系的体外活性比较

In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
PubMed 文献 · Br J Haematol · 2025-03-03

该体外研究比较了四种CD20xCD3生物类似双特异性抗体对四种CD20表达水平相差100倍的弥漫大B细胞淋巴瘤细胞系的活性。四种抗体体外活性均优于利妥昔单抗,生物类似格菲妥单抗 consistently 最强效;格菲妥单抗和奥妥珠单抗?原文为odronextamab。

要点

  • 四种CD20xCD3生物类似双特异性抗体体外活性均优于利妥昔单抗。
  • 生物类似格菲妥单抗在四种抗体中体外活性最强。
  • 格菲妥单抗和odronextamab在CD20低表达时仍保留显著活性。

核心结论

  • 四种CD20xCD3生物类似双特异性抗体体外活性均优于利妥昔单抗,生物类似格菲妥单抗最强效。

研究设计与样本

  • 体外研究,比较四种CD20xCD3生物类似双特异性抗体对四种CD20表达水平相差100倍的弥漫大B细胞淋巴瘤细胞系的活性。

主要发现

  • 四种CD20xCD3生物类似双特异性抗体体外活性均优于利妥昔单抗。
  • 生物类似格菲妥单抗在四种抗体中体外活性最强。
  • 生物类似格菲妥单抗和odronextamab在CD20低表达时仍保留显著活性。
  • 一种弥漫大B细胞淋巴瘤细胞系对四种CD20xCD3双特异性抗体均表现出内在耐药,尽管该细胞系可诱导显著的T细胞和NK细胞活化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B-cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ranging over a 100-fold. All four biosimilar BsAbs demonstrated superior in vitro activity to rituximab, with biosimilar glofitamab consistently being the most potent. Moreover, biosimilar glofitamab and odronextamab retained significant activity in the presence of low-level CD20 expression. Finally, one DLBCL cell line exhibited intrinsic resistance to all four CD20xCD3 BsAbs despite inducing marked T-cell and NK-cell activation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bray JS, Thomas GR, Smith VM, et al. In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20. Br J Haematol. 2025. PMID: 40032583. doi:10.1111/bjh.20033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。